← All drugs
Drug · FAERS side-effect profile with label screen

Valerian side effects: what 696 FDA adverse event reports show

Valerian · Valeriana Officinalis · 21 reaction terms · 187 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Valeriana Officinalis

openFDA label

Who reports

696 reports · 72% serious · 45 with death outcome · 65% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Relieves sleeplessness with hypersensitivity to stress Uses: See symptoms on front panel.

FDA label, Indications and Usage

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 16 strongest signals

Reporting / coding artifact 2Lab value / disease marker 1No label text to screen 13
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 5 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Renal tubular necrosis824.5
12.3–48.8ROR 24.8 · χ² 157 / p 2e-36
22.7 EB05 11.5 · IC025 +2.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 19.6no trial data cached
Nephropathy toxic924.3
12.7–46.6ROR 24.6 · χ² 179 / p 5e-41
22.9 EB05 12.3 · IC025 +2.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 19.8no trial data cached
Mydriasis818.8
9.4–37.4ROR 19.0 · χ² 118 / p 1e-27
16.8 EB05 7.6 · IC025 +2.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 19.3no trial data cached
Stevens-johnson syndrome (severe blistering skin reaction)1317.6
10.2–30.1ROR 17.9 · χ² 187 / p 8e-43
16.7 EB05 9.7 · IC025 +2.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 14.1no trial data cached
Restlessness1915.6
10.0–24.3ROR 16.0 · χ² 246 / p 1e-55
15.0 EB05 9.7 · IC025 +2.7
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 17.9no trial data cached
Ligament sprain515.3
6.4–36.5ROR 15.4 · χ² 53 / p 2e-13
10.8 EB05 3.7 · IC025 +1.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious n=5no trial data cached
Muscle rigidity615.1
6.8–33.5ROR 15.2 · χ² 66 / p 3e-16
11.5 EB05 4.4 · IC025 +1.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 13.5no trial data cached
Epilepsy1514.8
9.0–24.4ROR 15.1 · χ² 180 / p 3e-41
13.9 EB05 8.2 · IC025 +2.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 11.8no trial data cached
Gamma-glutamyltransferase increased1013.6
7.3–25.1ROR 13.8 · χ² 104 / p 9e-25
11.7 EB05 5.8 · IC025 +2.0
3/3 methods agree
Lab value / disease markerserious PRR 11.3no trial data cached
Nightmare1513.0
7.9–21.4ROR 13.3 · χ² 154 / p 1e-35
11.9 EB05 7.0 · IC025 +2.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 14.0no trial data cached
Tooth disorder912.1
6.3–23.2ROR 12.3 · χ² 81 / p 1e-19
9.8 EB05 4.8 · IC025 +1.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 14.8no trial data cached
Suicide attempt199.4
6.0–14.7ROR 9.6 · χ² 135 / p 2e-31
8.3 EB05 5.4 · IC025 +2.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 7.5no trial data cached
Intentional overdose146.6
3.9–11.1ROR 6.7 · χ² 61 / p 2e-15
5.6 EB05 3.5 · IC025 +1.6
3/3 methods agree
Reporting / coding artifactserious PRR 5.5no trial data cached
Tardive dyskinesia (persistent involuntary movements)55.3
2.2–12.6ROR 5.3 · χ² 13 / p 1e-4
3.8 EB05 1.8 · IC025 +0.4No label text to screen
label has no adverse-reaction text
serious PRR 4.0no trial data cached
Injection site haemorrhage93.4
1.8–6.5ROR 3.4 · χ² 13 / p 1e-4
3.0 EB05 1.7 · IC025 +0.5No label text to screen
label has no adverse-reaction text
serious PRR 13.5no trial data cached
Drug abuse72.5
1.2–5.3ROR 2.5 · χ² 5 / p 0.013
2.3 EB05 1.2 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Reporting / coding artifactserious PRR 2.0no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Suicide attempt199.4
6.0–14.7ROR 9.6 · χ² 135 / p 2e-31
8.3 EB05 5.4 · IC025 +2.2
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 7.5no trial data cached
Restlessness1915.6
10.0–24.3ROR 16.0 · χ² 246 / p 1e-55
15.0 EB05 9.7 · IC025 +2.7
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 17.9no trial data cached
Nightmare1513.0
7.9–21.4ROR 13.3 · χ² 154 / p 1e-35
11.9 EB05 7.0 · IC025 +2.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 14.0no trial data cached
Epilepsy1514.8
9.0–24.4ROR 15.1 · χ² 180 / p 3e-41
13.9 EB05 8.2 · IC025 +2.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 11.8no trial data cached
Intentional overdose146.6
3.9–11.1ROR 6.7 · χ² 61 / p 2e-15
5.6 EB05 3.5 · IC025 +1.6
3/3 methods agree
Reporting / coding artifactserious PRR 5.5no trial data cached
Stevens-johnson syndrome (severe blistering skin reaction)1317.6
10.2–30.1ROR 17.9 · χ² 187 / p 8e-43
16.7 EB05 9.7 · IC025 +2.5
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 14.1no trial data cached
Gamma-glutamyltransferase increased1013.6
7.3–25.1ROR 13.8 · χ² 104 / p 9e-25
11.7 EB05 5.8 · IC025 +2.0
3/3 methods agree
Lab value / disease markerserious PRR 11.3no trial data cached
Injection site haemorrhage93.4
1.8–6.5ROR 3.4 · χ² 13 / p 1e-4
3.0 EB05 1.7 · IC025 +0.5No label text to screen
label has no adverse-reaction text
serious PRR 13.5no trial data cached
Tooth disorder912.1
6.3–23.2ROR 12.3 · χ² 81 / p 1e-19
9.8 EB05 4.8 · IC025 +1.8
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 14.8no trial data cached
Nephropathy toxic924.3
12.7–46.6ROR 24.6 · χ² 179 / p 5e-41
22.9 EB05 12.3 · IC025 +2.3
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 19.8no trial data cached
Mydriasis818.8
9.4–37.4ROR 19.0 · χ² 118 / p 1e-27
16.8 EB05 7.6 · IC025 +2.0
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 19.3no trial data cached
Renal tubular necrosis824.5
12.3–48.8ROR 24.8 · χ² 157 / p 2e-36
22.7 EB05 11.5 · IC025 +2.1
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 19.6no trial data cached
Drug abuse72.5
1.2–5.3ROR 2.5 · χ² 5 / p 0.013
2.3 EB05 1.2 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Reporting / coding artifactserious PRR 2.0no trial data cached
Muscle rigidity615.1
6.8–33.5ROR 15.2 · χ² 66 / p 3e-16
11.5 EB05 4.4 · IC025 +1.4
3/3 methods agree
No label text to screen
label has no adverse-reaction text
serious PRR 13.5no trial data cached
Tardive dyskinesia (persistent involuntary movements)55.3
2.2–12.6ROR 5.3 · χ² 13 / p 1e-4
3.8 EB05 1.8 · IC025 +0.4No label text to screen
label has no adverse-reaction text
serious PRR 4.0no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Valerian?

In FDA FAERS, the most frequently co-reported reaction terms for Valerian are suicide attempt, restlessness, nightmare, epilepsy, stevens-johnson syndrome, gamma-glutamyltransferase increased. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Valerian have an FDA boxed warning?

No. The FDA label retrieved for Valerian has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Valerian causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.